Literature DB >> 24197757

Breast-conservative surgery with and without radiotherapy in patients aged 55-75 years with early-stage breast cancer: a prospective, randomized, multicenter trial analysis after 108 months of median follow-up.

C Tinterri1, W Gatzemeier, A Costa, M A Gentilini, V Zanini, L Regolo, C Pedrazzoli, E Rondini, C Amanti, G Gentile, M Taffurelli, P Fenaroli, C Tondini, G Sacchetto, P Sismondi, R Murgo, M Orlandi, E Cianchetti, C Andreoli.   

Abstract

OBJECTIVES: Breast-conserving therapy (BCT), including postoperative whole breast irradiation (WBI), is generally accepted as the treatment of choice for most patients with early-stage breast cancer. The question whether WBI is mandatory in all patients remains one of the most controversial issues in BCT. To answer this question, a randomized, prospective, multicentre study was launched in January 2001. Primary endpoints of the study were to assess the cumulative incidence of in-breast-recurrences (IBR) and overall survival (OAS) after conservative surgery (BCS) with or without WBI.
METHODS: From January 2001 until December 2005, 749 patients with unifocal infiltrating breast cancer up to 25 mm, 0-3 positive axillary lymph nodes, no extensive intraductal component or lymphvascular invasion from 11 centres in Italy, were randomly assigned to BCS+WBI (arm 1:373 patients) or BCS alone (arm 2:376 patients). Treatment arms were well balanced in terms of baseline characteristics. Systemic adjuvant therapy was administered according to the institutional policies. Kaplan-Meier method was used for survival analysis and log-rank test to evaluate the difference between the two arms. RESULTS (Last analysis 31.12.2012): After median follow-up of 108 months, 12 (3.4%) IBR were observed in arm 1 and 16 (4.4%) in arm 2. OAS was 81.4% in arm 1 and 83.7% in arm 2. There was no statistically significant difference regarding IBR and death in the two treatment groups.
CONCLUSIONS: These data are promising and suggest that WBI after BCS can be omitted in selected patients with early stage breast cancer without exposing them to an increased risk of local recurrence and death. Longer follow-up is needed to further consolidate these results.

Entities:  

Mesh:

Year:  2013        PMID: 24197757     DOI: 10.1245/s10434-013-3233-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy.

Authors:  Michela Dispinzieri; Eliana La Rocca; Elisabetta Meneghini; Alba Fiorentino; Laura Lozza; Serena Di Cosimo; Massimiliano Gennaro; Vito Cosentino; Milena Sant; Emanuele Pignoli; Riccardo Valdagni; Francesca Bonfantini; Maria Carmen De Santis
Journal:  Med Oncol       Date:  2018-06-16       Impact factor: 3.064

2.  Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer.

Authors:  Anita Mamtani; Julie J Gonzalez; Dayna T Neo; Robb S Friedman; Abram Recht; Michele R Hacker; Ranjna Sharma
Journal:  Ann Surg Oncol       Date:  2018-02-09       Impact factor: 5.344

3.  [Adjuvant radiotherapy in low-risk breast cancer: long-term results of the ABCSG-8A trial].

Authors:  David Krug; Marciana-Nona Duma
Journal:  Strahlenther Onkol       Date:  2020-07       Impact factor: 3.621

4.  A Network Meta-Analysis of Surgical Treatment in Patients With Early Breast Cancer.

Authors:  Yu Gui; Xunzhou Liu; Xianchun Chen; Xi Yang; Shichao Li; Qingwen Pan; Xiangdong Luo; Li Chen
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

Review 5.  De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients.

Authors:  Pierfrancesco Franco; Giuseppe Carlo Iorio; Sara Bartoncini; Mario Airoldi; Corrado De Sanctis; Isabella Castellano; Umberto Ricardi
Journal:  Med Oncol       Date:  2018-04-03       Impact factor: 3.064

6.  Older age and comorbidity in breast cancer: is RT alone the new therapeutic frontier?

Authors:  E La Rocca; E Meneghini; L Lozza; A Fiorentino; A Vitullo; C Giandini; F Bonfantini; S Di Cosimo; M Gennaro; M Sant; E Pignoli; R Valdagni; Maria Carmen De Santis
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-13       Impact factor: 4.553

7.  Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial.

Authors:  Jean-Michel Hannoun-Levi; Emmanuel Chamorey; Rabia Boulahssass; Csaba Polgar; Vratislav Strnad
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-22

Review 8.  Omission of adjuvant radiotherapy for older adults with early-stage breast cancer particularly in the COVID era: A literature review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology).

Authors:  Isabella Palumbo; Simona Borghesi; Fabiana Gregucci; Sara Falivene; Antonella Fontana; Cynthia Aristei; Antonella Ciabattoni
Journal:  J Geriatr Oncol       Date:  2021-05-18       Impact factor: 3.599

9.  Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 2--TARGIT.

Authors:  Melvin J Silverstein; Gerd Fastner; Sergio Maluta; Roland Reitsamer; Donald A Goer; Frank Vicini; David Wazer
Journal:  Ann Surg Oncol       Date:  2014-08-20       Impact factor: 5.344

10.  Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis.

Authors:  Xuan-Zhang Huang; You Chen; Wen-Jun Chen; Xi Zhang; Cong-Cong Wu; Chao-Ying Zhang; Shuang-Shuang Sun; Jian Wu
Journal:  Oncotarget       Date:  2017-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.